TGFB1 and glioblastoma: In this vein, our group has recently reported single-agent activity of the FDA-approved, commonly prescribed, well-tolerated cholesterol-lowering drug simvastatin against models of human GBM, mechanistically through inhibition of the pro-oncogenic TGF-β signaling pathway [7].